DAPA-HF
Dapagliflozin and Prevention of Adverse outcomes in Heart Failure
Patient / Population Intervention / Exposure Comparison Outcome
In 4,744 patients with HFrEF (with or without diabetes), dapagliflozin reduced worsening HF or CV death versus placebo.
N
4,744
Design
Double-blind RCT, median 18 mo
Endpoint
Worsening HF or CV death
Relevance
1
Result16.3 % vs 21.2 % (HR 0.74). Benefit independent of diabetes.
McMurray JJV, et al. N Engl J Med. 2019;381(21):1995-2008. 10.1056/NEJMoa1911303
Discussion & critique
Defined SGLT2i as a fourth GDMT pillar. EMPEROR-Reduced confirmed class effect. Dapagliflozin/empagliflozin now standard regardless of diabetes status.